EI

253.2

-4.85%↓

SHL.DE

48.12

-2.83%↓

ARGX

544.8

+3.53%↑

FRE

39.61

+2.25%↑

PHIA

22.65

-1.22%↓

EI

253.2

-4.85%↓

SHL.DE

48.12

-2.83%↓

ARGX

544.8

+3.53%↑

FRE

39.61

+2.25%↑

PHIA

22.65

-1.22%↓

EI

253.2

-4.85%↓

SHL.DE

48.12

-2.83%↓

ARGX

544.8

+3.53%↑

FRE

39.61

+2.25%↑

PHIA

22.65

-1.22%↓

EI

253.2

-4.85%↓

SHL.DE

48.12

-2.83%↓

ARGX

544.8

+3.53%↑

FRE

39.61

+2.25%↑

PHIA

22.65

-1.22%↓

EI

253.2

-4.85%↓

SHL.DE

48.12

-2.83%↓

ARGX

544.8

+3.53%↑

FRE

39.61

+2.25%↑

PHIA

22.65

-1.22%↓

Sanofi SA

Отворен

СекторЗдравеопазване

100.96 1.98

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

98.88

Максимум

101.9

Ключови измерители

By Trading Economics

Приходи

-2.3B

499M

Продажби

-6.5B

7.6B

P/E

Средно за сектора

23.216

63.778

EPS

1.31

Дивидентна доходност

3.79

Марж на печалбата

6.539

Служители

82,878

EBITDA

-3.7B

563M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+13.3% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

3.79%

2.39%

Следващи печалби

24.04.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-6B

125B

Предишно отваряне

98.98

Предишно затваряне

100.96

Настроения в новините

By Acuity

33%

67%

106 / 386 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

Sanofi SA Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

20.03.2025 г., 06:43 ч. UTC

Придобивния, сливания и поглъщания

Sanofi to Acquire Autoimmune Disease Treatment From Dren Bio for Up to $1.9 Billion

5.02.2025 г., 13:41 ч. UTC

Печалби

Santander Shares Get Boost From Buyback, Better-Than-Expected Results -- 2nd Update

5.02.2025 г., 07:10 ч. UTC

Печалби

Santander Plans $10.4 Billion in Buybacks After Results Beat Expectations -- Update

5.02.2025 г., 06:39 ч. UTC

Печалби

Santander Plans $10.4 Billion in Buybacks After Results Beat Expectations

2.04.2025 г., 13:44 ч. UTC

Пазарно говорене

Santander Push Into Canada on the Cards -- Market Talk

2.04.2025 г., 09:27 ч. UTC

Горещи акции

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

26.03.2025 г., 06:19 ч. UTC

Пазарно говорене
Печалби

Santander Surpasses 100 Billion-Euro Valuation Milestone -- Market Talk

25.03.2025 г., 10:08 ч. UTC

Пазарно говорене

Santander Needs Step-Up in Profitability to Fully Close Discount -- Market Talk

20.03.2025 г., 09:00 ч. UTC

Топ новини

'Anti-Woke' in the U.S., DEI at Home: the New Playbook for European Companies -- WSJ

20.03.2025 г., 06:05 ч. UTC

Придобивния, сливания и поглъщания

Sanofi: Deal Seeks to Broaden Immunology Pipeline

20.03.2025 г., 06:05 ч. UTC

Придобивния, сливания и поглъщания

Sanofi to Make Potential Future Payments Totaling $1.3B Upon Reaching Milestones

20.03.2025 г., 06:04 ч. UTC

Придобивния, сливания и поглъщания

Sanofi to Pay $600M Upfront

20.03.2025 г., 06:02 ч. UTC

Придобивния, сливания и поглъщания

Sanofi to Buy Dren Bio's Bispecific Myeloid Cell Engager

20.03.2025 г., 06:00 ч. UTC

Придобивния, сливания и поглъщания

Press Release: Sanofi To Acquire Dren Bio's Bispecific Myeloid Cell Engager For Deep B-cell Depletion, Broadening Immunology Pipeline >SAN.FR

18.03.2025 г., 09:33 ч. UTC

Горещи акции

Stocks to Watch Tuesday: Nvidia, BYD, Santander, Google -- WSJ

17.03.2025 г., 23:00 ч. UTC

Топ новини

Santander Pushes to Expand U.S. Operations by Utilizing Verizon Customer Base -- WSJ

13.03.2025 г., 09:50 ч. UTC

Печалби

Santander Approves Final Cash Dividend Per Share of EUR11 cents

13.03.2025 г., 09:49 ч. UTC

Печалби

Santander Increased 2024 Cash Payments by 19%

24.02.2025 г., 08:56 ч. UTC

Пазарно говорене
Печалби

European Banks' Quarterly Beats Confirm Momentum -- Market Talk

24.02.2025 г., 08:30 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Southern European Banks' Strong Finish to 2024 Confirms Attractiveness -- Market Talk

19.02.2025 г., 06:35 ч. UTC

Придобивния, сливания и поглъщания

Sanofi: Transaction Remains Subject to Obtaining Customary Regulatory Approvals

19.02.2025 г., 06:34 ч. UTC

Придобивния, сливания и поглъщания

Sanofi: Closing Is Expected to Take Place in 2Q at the Earliest

19.02.2025 г., 06:34 ч. UTC

Придобивния, сливания и поглъщания

Sanofi: Terms of Transaction Remain Unchanged From Those Previously Disclosed

19.02.2025 г., 06:33 ч. UTC

Придобивния, сливания и поглъщания

Sanofi to Remain Significant Shareholder in Opella Consumer Business

19.02.2025 г., 06:33 ч. UTC

Придобивния, сливания и поглъщания

Sanofi: Bpifrance to Participate as Minority Shareholder With 2% Stake in Opella

19.02.2025 г., 06:33 ч. UTC

Придобивния, сливания и поглъщания

Sanofi: This Follows Completion of Required Social and Corporate Procedures

19.02.2025 г., 06:32 ч. UTC

Придобивния, сливания и поглъщания

Sanofi Signs Deal for Sale of 50% Controlling Stake in Opella to CD&R

19.02.2025 г., 06:31 ч. UTC

Придобивния, сливания и поглъщания

Sanofi, CD&R Sign Opella Share Purchase Agreement

14.02.2025 г., 10:55 ч. UTC

Пазарно говорене
Печалби
Придобивния, сливания и поглъщания

NatWest CEO Confident on Organic Growth Prospects -- Market Talk

5.02.2025 г., 07:48 ч. UTC

Пазарно говорене
Печалби

Santander's Results, Guidance, Return Plans All Look Strong -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Sanofi SA Прогноза

Ценова цел

By TipRanks

13.3% нагоре

12-месечна прогноза

Среден 115.584 EUR  13.3%

Висок 125 EUR

Нисък 92 EUR

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Sanofi SA през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

13 ratings

9

Купи

4

Задържане

0

Продай

Техническа оценка

By Trading Central

101.44 / 102.7Подкрепа & съпротива

Краткосрочен план

Bearish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

106 / 386 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.